---
title: "BioKangtai and AstraZeneca sign a license termination agreement"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/259474198.md"
description: "BioKangtai and AstraZeneca signed a termination agreement to end the research, production, and commercialization cooperation of the ChAdOx1 adenovirus vector COVID-19 vaccine. Due to changes in the market environment and the impact of COVID-19 vaccine variants, both parties decided to terminate the original licensing agreement after friendly consultations, with all rights and obligations ending from the effective date of the new agreement"
datetime: "2025-09-30T08:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259474198.md)
  - [en](https://longbridge.com/en/news/259474198.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259474198.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/259474198.md) | [English](https://longbridge.com/en/news/259474198.md)


# BioKangtai and AstraZeneca sign a license termination agreement

According to the Zhitong Finance APP, BioKangtai (300601.SZ) announced that on August 20, 2020, the company signed a License Agreement with AstraZeneca UK Limited (hereinafter referred to as "AstraZeneca"), granting AstraZeneca exclusive authorization for the company to conduct research and development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine (hereinafter referred to as "licensed product") within the People's Republic of China (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan).

In light of significant changes in the domestic and international COVID-19 vaccine strains and market environment, both parties have decided to terminate the cooperation on the research and development, production, and commercialization of the licensed product (ChAdOx1 adenovirus vector COVID-19 vaccine) through friendly consultation. Recently, they signed a License Termination Agreement, and all rights and obligations under the original License Agreement will terminate upon the effective date of the License Termination Agreement signed by both parties

### 相關股票

- [BioKangtai (300601.CN)](https://longbridge.com/zh-HK/quote/300601.CN.md)

## 相關資訊與研究

- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-HK/news/281035304.md)
- [PetroChina Renews Financial Deal With Related Company](https://longbridge.com/zh-HK/news/280998322.md)
- [Seres Group Unveils Audited 2025 Results and Proposes Robust Cash Dividend](https://longbridge.com/zh-HK/news/280988702.md)
- [Samsung Biologics labor union members have overwhelmingly voted in favor of strike, with 95.52% voting in favor on 95.38% turnout](https://longbridge.com/zh-HK/news/281030155.md)
- [Precise Biometrics Calls EGM to Approve Merger With Fingerprint Cards](https://longbridge.com/zh-HK/news/281003945.md)